Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23000 UNIT/23 ML SUBCUT SOLN (NDC 5024255401) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved October 29, 2026 , from http://ppman.hank.ai/transparency/procedure/5024255401/by-state?code_type=NDC
“OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23000 UNIT/23 ML SUBCUT SOLN (NDC 5024255401) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/5024255401/by-state?code_type=NDC. Accessed
October 29, 2026 .
“OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23000 UNIT/23 ML SUBCUT SOLN (NDC 5024255401) by State,” HANK Price Transparency ,
accessed October 29, 2026 ,
http://ppman.hank.ai/transparency/procedure/5024255401/by-state?code_type=NDC.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
NDC · across United States
5024255401 — Ocrelizumab 920 Mg-hyaluronidase-ocsq 23000 Unit/23 Ml Subcut Soln
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$14,183
National median
$54 – $15,276
IQR (p25 – p75)
7
hospitals filing
2
states
Walking in without insurance?
Cash / self-pay price
Cash median
$21,879
vs. negotiated
+54.3%
Hospitals reporting
7
Cash / self-pay rates apply when you don't run the bill through insurance.
Many hospitals also offer income-based discounts on top of the published
cash price — always ask about a financial-assistance application
before paying.
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 5024255401 (NDC), with interquartile range
State Median p25 p75
VA $44,259 $28,536 $76,521
PA $8,325 $51 $15,276